These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 30413856)

  • 1. Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations.
    Hamood R; Hamood H; Merhasin I; Keinan-Boker L
    Osteoporos Int; 2019 Jan; 30(1):187-200. PubMed ID: 30413856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes After Hormone Therapy in Breast Cancer Survivors: A Case-Cohort Study.
    Hamood R; Hamood H; Merhasin I; Keinan-Boker L
    J Clin Oncol; 2018 Jul; 36(20):2061-2069. PubMed ID: 29688833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
    Bromley SE; Matthews A; Smeeth L; Stanway S; Bhaskaran K
    J Cancer Surviv; 2019 Aug; 13(4):632-640. PubMed ID: 31321612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis.
    Chen J; Zhang X; Lu Y; Zhang T; Ouyang Z; Sun Q
    Breast Cancer; 2021 May; 28(3):630-643. PubMed ID: 33387283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
    Cepa M; Vaz C
    Acta Reumatol Port; 2015; 40(4):323-30. PubMed ID: 26922195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study of lifestyle factors and bone health in breast cancer patients who received aromatase inhibitors in an integrated healthcare setting.
    Kwan ML; Lo JC; Laurent CA; Roh JM; Tang L; Ambrosone CB; Kushi LH; Quesenberry CP; Yao S
    J Cancer Surviv; 2023 Feb; 17(1):139-149. PubMed ID: 33565036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors.
    Chlebowski RT; Schottinger JE; Shi J; Chung J; Haque R
    Cancer; 2015 Jul; 121(13):2147-55. PubMed ID: 25757699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
    Xu X; Chlebowski RT; Shi J; Barac A; Haque R
    Breast Cancer Res Treat; 2019 Apr; 174(3):785-794. PubMed ID: 30659431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer.
    Gupta T; Purington N; Liu M; Han S; Sledge G; Schapira L; Kurian AW
    Breast Cancer Res Treat; 2022 Nov; 196(1):175-183. PubMed ID: 36030472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study.
    Ramin C; May BJ; Roden RBS; Orellana MM; Hogan BC; McCullough MS; Petry D; Armstrong DK; Visvanathan K
    Breast Cancer Res; 2018 Nov; 20(1):134. PubMed ID: 30424783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer.
    Haque R; Ahmed SA; Fisher A; Avila CC; Shi J; Guo A; Craig Cheetham T; Schottinger JE
    Cancer Med; 2012 Dec; 1(3):318-27. PubMed ID: 23342281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of aromatase inhibitors on bone metabolism].
    Folkestad L; Bjerregaard JK; Bjarnason NH; Brixen KT
    Ugeskr Laeger; 2007 May; 169(19):1774-9. PubMed ID: 17537350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
    Eastell R; Hannon RA; Cuzick J; Dowsett M; Clack G; Adams JE;
    J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients.
    Neuner JM; Yen TW; Sparapani RA; Laud PW; Nattinger AB
    Osteoporos Int; 2011 Nov; 22(11):2847-55. PubMed ID: 21170643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.
    Brier MJ; Chambless DL; Chen J; Mao JJ
    Eur J Cancer; 2018 Mar; 91():145-152. PubMed ID: 29329697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
    Leslie WD; Morin SN; Lix LM; Niraula S; McCloskey EV; Johansson H; Harvey NC; Kanis JA
    J Bone Miner Res; 2019 Aug; 34(8):1428-1435. PubMed ID: 31069862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of bone mineral density screening on incident fractures and healthcare resource utilization among postmenopausal breast cancer survivors treated with aromatase inhibitors.
    Bailey S; Mhango G; Lin JJ
    Osteoporos Int; 2022 Sep; 33(9):1989-1997. PubMed ID: 35697870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease Progression Modeling Analysis of the Change of Bone Mineral Density by Postoperative Hormone Therapies in Postmenopausal Patients With Early Breast Cancer.
    Yoon S; Bae KS; Cho YS; Han S; Kim H; Lim HS
    J Clin Pharmacol; 2019 Nov; 59(11):1543-1550. PubMed ID: 31172521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
    Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
    J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.